We think Shola Ameobi is almost odds on to leave Newcastle United in the January transfer window with quite a number of clubs seemingly interested to take the Newcastle striker.
Bolton Wanderers are just one of a number of Premier League and Championship clubs prepared to bid for the Newcastle striker, whose time seems almost up at Newcastle.
Shola Ameobi – time seems up for Shola at Newcastle
Newcastle manager Sam Allardyce has not received any enquiries for the former England Under-21 international, but scouts were out in abundance during Newcastleâ€™s reserve game against Everton on Tuesday night, in which Shola scored a penalty.
Ameobi has only started one Premier League match under Allardyce, against Derby County back in September, and he has a terrible game, to put it mildly. But so did a lot of other Newcastle players that night against the Premier leagueâ€™s bottom team.
Shola has been a peripheral figure under Allardyce at a stage of his career when he needs regular first-team football, and the fact he has not even made the bench when both Viduka and Smith have been out of the side, tells it all.
Newcastle will need to move some players out in January to make room for new recruits and we think Shola will be moved on. He is valued by the club at around Â£2M and a move to Bolton could appeal to the player.
Norwich City, under new manager Glenn Roeder, are also interested â€“ but only in taking Ameobi on loan for the rest of the season to boast their bid to get out of relegation trouble in the Championship. That does not seem to be too good a deal for Newcastle, who we think would prefer to get the Â£2M fee for the player, in a transfer deal in January.
There could well be other clubs come in for Shola shortly â€“ but we donâ€™t expect him to be a Newcastle player come the end of January. Time has caught up with the Nigerian at Newcastle, where he has failed to prove heâ€™s good enough for the team.
What do you think? Should Ameobi be one of the players jettisoned in January?
Let us know – comments always welcome.